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Abstract
Purpose: The main purpose of this study is to demonstrate the clinical implementa-
tion of a comprehensive pencil beam scanning (PBS) daily quality assurance (QA)
program involving a number of novel QA devices including the Sphinx/Lynx/parallel‐
plate (PPC05) ion chamber and HexaCheck/multiple imaging modality isocentricity
(MIMI) imaging phantoms. Additionally, the study highlights the importance of test-
ing the connectivity among oncology information system (OIS), beam delivery/imag-
ing systems, and patient position system at a proton center with multi‐vendor
equipment and software.
Methods: For dosimetry, a daily QA plan with spot map of four different energies
(106, 145, 172, and 221 MeV) is delivered on the delivery system through the OIS.
The delivery assesses the dose output, field homogeneity, beam coincidence, beam
energy, width, distal-fall-off (DFO), and spot characteristics — for example, position,
size, and skewness. As a part of mechanical and imaging QA, a treatment plan with
the MIMI phantom serving as the patient is transferred from OIS to imaging system.
The HexaCheck/MIMI phantoms are used to assess daily laser accuracy, imaging
isocenter accuracy, image registration accuracy, and six‐dimensional (6D) positional
correction accuracy for the kV imaging system and robotic couch.
Results: The daily QA results presented herein are based on 202 daily sets of mea-
surements over a period of 10 months. Total time to perform daily QA tasks at our
center is under 30 min. The relative difference (Δrel) of daily measurements with
respect to baseline was within ± 1% for field homogeneity, ±0.5 mm for range,
width and DFO, ±1 mm for spots positions, ±10% for in‐air spot sigma, ±0.5 spot
skewness, and ±1 mm for beam coincidence (except 1 case: Δrel = 1.3 mm). The
average Δrel in dose output was −0.2% (range: −1.1% to 1.5%). For 6D IGRT QA,
the average absolute difference (Δabs) was ≤0.6 ± 0.4 mm for translational and
≤0.5° for rotational shifts.
Conclusion: The use of novel QA devices such as the Sphinx in conjunction with
the Lynx, PPC05 ion chamber, HexaCheck/MIMI phantoms, and myQA software
was shown to provide a comprehensive and efficient method for performing daily
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QA of a number of system parameters for a modern proton PBS‐dedicated treat-
ment delivery unit.
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1 | INTRODUCTION
The number of proton therapy centers in the US continues to grow
as there is an increasing interest in the use of protons to treat can-
cer patients.1 Currently, proton centers employ different beam deliv-
ery techniques such as double scattering (DS), uniform scanning (US),
and/or pencil beam scanning (PBS). In the last few years, a number
of existing proton centers have upgraded their beam delivery tech-
nique from DS/US to PBS. The majority of new proton centers is
now configured with a more advanced PBS beam delivery technique
that has been shown to deliver a more conformal dose when com-
pared to DS/US techniques.2 However, PBS proton beam delivery
has uncertainties associated with its spot size and spatial position.
Such demand for advanced PBS delivery warrants a comprehensive
understanding and monitoring of PBS beam characteristics. In addi-
tion to advances in proton beam delivery, image guidance used for
proton treatments has also evolved in recent years. In the past, the
primary imaging modality in proton centers had been planar kV x‐ray
technique. Newer proton centers are incorporating imaging modali-
ties such as cone‐beam computed tomography (CBCT) and surface
imaging (SGRT). Due to the increase in delivery complexity of PBS
and the use of multi‐modality image‐guidance systems for patient
treatments, there is a need to establish a comprehensive daily quality
assurance (QA) program that assesses safety, mechanical, dosimetric,
and imaging parameters to ensure safe radiation delivery — similar
to the recommendations set forth by AAPM TG‐142 for photon‐
based delivery systems. Additionally, certain proton centers may
employ multi‐vendor hardware and software for daily patient treat-
ment. For these centers, interconnectivity becomes a critical element
to assess and testing of data transfer among different softwares
(e.g., beam delivery, imaging, record, verify systems, etc.) should be
integrated as part of the daily QA program.
Several authors have published on proton daily QA using either
commercial or in‐house developed devices.3–9 Arjomandy et al.3 pub-
lished a paper in 2009 providing an overview of QA procedures
implemented at The University of Texas M. D. Anderson Proton
Therapy Center at Houston (PTC‐H). Arjomandy et al.3 verified the
output, distal range, and spread‐out Bragg Peak (SOBP) for daily QA
of DS proton beams using the solid‐water plastic. In 2012, Ding et
al.4 initially investigated the use of Sun Nuclear Daily‐QA 3 (DQA‐3)
device (Sun Nuclear Inc., Melbourne, FL, USA) for daily QA of US
proton beams. In 2014, Lambert et al.5 extended the use of DQA‐3
for daily QA of PBS proton beams. For PBS dosimetric tests,
Lambert et al.5 evaluated the output, range, spot sigma, and position.
Since the DQA‐3 was originally designed for photon and electron
daily QA, authors4,5 manufactured an in‐house phantom to use with
the DQA‐3. Actis et al.6 published on PBS daily QA in 2017 utilizing
an in‐house developed phantom that can accommodate multi‐leaf
ionization chamber (MLIC). Actis et al.6 included beam characteristics
(spot width, size, and position), range, and dose output for the dosi-
metric component of daily QA. Another PBS daily QA paper was
published in 2017 by Bizzocchi et al.7 and investigated the use of
MatriXX‐PT (IBA Dosimetry, Schwarzenbruck, Germany) with an in‐
house phantom to evaluate range, spot size and position, and dose
output. In a more recent paper, Younkin et al.8 utilized the DQA‐3
along with an in‐house developed phantom to evaluate dose output,
beam range, and spot position as part of PBS daily QA.
The above‐mentioned studies4–8 demonstrate that investigators
have used in‐house developed phantoms and software in conjunction
with commercially available devices for PBS daily QA. Moreover, the
detectors used in previous PBS Daily QA studies4–8 were limited to
DQA‐3, MLIC, and MatriXX‐PT. Recently, a novel PBS dedicated com-
mercial device Sphinx (IBA Dosimetry, Schwarzenbruck, Germany) has
been made available to proton therapy centers. In order to be able to
quantify specific PBS beam characteristics, the Sphinx must be used in
conjunction with the Lynx (IBA Dosimetry, Schwarzenbruck, Germany)
and a parallel‐plate (PPC05) ionization chamber (IBA Dosimetry, Sch-
warzenbruck, Germany). Given the novelty of the device and no pub-
lished literature on the experience of the Sphinx and Lynx for PBS daily
QA, this work focuses on our clinical implementation and long‐term
results when incorporating these devices for the dosimetric component
of our PBS daily QA. In addition to evaluating the dosimetric compo-
nent of PBS proton beams, this work highlights the importance of a
comprehensive daily QA program and addresses the need to develop
other components such as safety, mechanical, and imaging tests to
ensure safe radiotherapy treatment deliveries. Daily QA tests presented
in this work may serve beneficial to proton centers looking to develop
and implement a comprehensive daily QA program based on recently
developed commercially available detectors and phantoms.
2 | MATERIALS AND METHODS
Our proton center is structured as a multi‐vendor hardware and soft-
ware platform environment. PBS proton plans are generated in
RayStation (v.6.1.1.2; RaySearch Laboratories, Stockholm, Sweden),
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whereas ARIA (v.13.7; Varian Medical Systems, Palo Alto, CA) is
used as the department record and verify system. IBA (Ion Beam
Applications, Louvain‐la‐Neuve, Belgium) provides the ProteusPLUS
PBS proton therapy system, which includes adaPT‐Deliver (v.11.0.3)
for beam delivery and adaPT‐Insight (v.2.1.0d) for imaging (kV‐kV x
ray and kV‐CBCT). Additionally, the CatalystPT (C‐RAD, Uppsala,
Sweden) system is used for surface imaging and gating applications.
The flow chart of data transfer among the various software entities
is presented in Fig. 1.
2.A | Beam delivery system (BDS)
A PBS proton beam is delivered using a PBS dedicated nozzle
(Fig. 2). As the proton beam enters the nozzle, an ionization chamber
1 (IC1) verifies the alignment of the beam at the nozzle entrance. A
set of two focusing quadrupole magnets focus the proton beam at
the isocenter. The proton beam is then scanned in Y direction by a
vertical scanning magnet followed by scanning in X direction with a
horizontal scanning magnet. In order to direct the beam to a particu-
lar location on a target, the beam position is steered using magnetic
fields. Ionization chambers 2 and 3 (IC2/3) monitor beam characteris-
tics real‐time (beam size, position, and flatness) and dose just before
the proton beam exists the nozzle. Snout holder allows the move-
ment of accessary drawer, which can include an optional range shif-
ter (pre‐absorber) and snout. At our center, a range shifter of 7.5 cm
water equivalent thickness is used for clinical cases as necessary.
2.B | Imaging systems
The kV x‐ray imaging system includes two gantry mounted, x‐ray
tubes that rotate with the gantry. The first x‐ray tube (portal) is
located in the PBS dedicated nozzle pre‐assembly, which is under
vacuum. The x‐ray tube is retracted from the beam line during the
proton beam irradiation. The flat panel detector of portal (SAD =
119.4 cm, SID = 177.0 cm, active pixel area = 28.2 cm × 40.6 cm,
and active pixel resolution: 2232 × 3200 pixels) is located in front of
the nozzle. The second x‐ray tube (orthogonal) is fixed to one of the
gantry structural beams. The x‐ray beam axis is perpendicular to the
proton beam axis and to the gantry rotation axis. The orthogonal
tube in conjunction with its flat panel detector (SAD = 264.2 cm,
SID = 317.1 cm, active pixel area = 43 cm × 43 cm, and active pixel
resolution: 2874 × 2840 pixels) is used for the kV‐CBCT acquisition.
In addition to the x ray based imaging system, the CatalystPT, a
three‐camera surface imaging system, is used to setup patients prior
to x ray based imaging, monitor patient position and posture during
treatment, and enable beam gating. The three cameras are posi-
tioned to maximize field coverage with the outer cameras being 43°
from the center camera.
2.C | Record and verify system
ARIA (v13.7) receives computed tomography (CT) images, DICOM
structure set, RT Plan, RT Dose, and DRR images from RayStation.
ARIA also receives the treatment record from adaPT Deliver and
images (kV planar/CBCT images) from adaPT Insight.
2.D | Phantoms and detectors
The Sphinx phantom has a carbon frame with dimension of
540 mm × 400 mm × 400 mm (Fig. 3). The carbon frame contains
the markers for verification of laser alignment. The phantom incorpo-
rates four wedges with various thicknesses for verifying the con-
stancy of different proton beam energies (106, 145, 172, and
221 MeV). The fixed solid water block (RW3) and insert RW3 have
mass density of 1.045 g/cm3 and electron density of 3.386 × 1023/
cm3. The RW3 insert has dimensions of 35 mm width, 100 mm
height, and variable length (250, 200, and 100 mm).
The four wedges are utilized to calculate the energy related
parameters such as range, width, and distal-fall-off (DFO). The
energy calculation algorithm10 implemented within myQA software,
version 2017‐002 (2.9.23.0) calculates the slight signal generated by
the radiation delivered over the RW3 wedge. The first derivative of
F I G . 1 . Flow chart of data transfer
among RayStation, ARIA, adaPT‐Deliver
(beam delivery), and adaPT‐Insight
(imaging) in a ProteusPLUS pencil beam
scanning proton therapy system.
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this rising part of signal is then calculated in order to identify the
physical edge of the corresponding RW3 block.10 The final depth‐
dose curve is calculated by assigning a value of depth to each pixel
of the image.10 The values of depths are extrapolated from data
interpolated with a cubic spline fit.10 For better understanding on
the range calculation using wedge, readers are advised to refer to
work published by Shen et al.11 and Deng et al.12
The phantom also has an insert containing a pin with a fiducial at
its tip which is placed at the isocenter (Fig. 3). A dedicated RW3
insert (160 mm × 90 mm × 100 mm) contains a notch for a PPC05
chamber for dose output constancy check. The PPC05 is covered
with 3 cm thickness RW3 block so the chamber has a 3 cm build up
(Fig. 3). The PPC05 chamber can then be connected to an electrom-
eter for dose output measurement. The phantom setup allows the
in‐air measurement of spots at the level of the Lynx. The Lynx is a
gadolinium‐based scintillation detector (active surface area = 300
mm × 300 mm) with a pixel resolution of 0.5 mm. A detailed
description of the Lynx is provided by Russo et al.13
For imaging quality assurance, the multiple imaging modality
isocentricity (MIMI) phantom along with the HexaCheck phantom
(Standard Imaging, Middleton, WI, USA) are used to perform daily,
six‐dimensional (6D) image‐guided radiation therapy (IGRT) QA of
the IBA adaPT‐Insight software and LEONI (LEONI Healthcare, Char-
tres France) robotic couch. The HexaCheck acts as a base for the
MIMI phantom and allows for the introduction of a fixed 2.5°
mechanical displacement in the yaw, pitch, and roll directions. For
more information on the clinical use of MIMI and HexaCheck, read-
ers are advised to refer to white paper.14
F I G . 2 . Schematic representation of the beam delivery system equipment in the pencil beam scanning (PBS) treatment mode for an IBA
ProteusPLUS gantry‐based system. Note: The x‐ray tube (portal) is located in the PBS dedicated nozzle pre‐assembly, which is under vacuum.
The x‐ray tube is retracted from the beam line during proton beam irradiation.
(a)
(c) (d)
(b)
F I G . 3 . (a) The Sphinx device is shown
with the fiducial insert for x‐ray vs proton
beam coincidence. (a‐c) The RW3 blocks
with wedges (W1, W2, W3, and W4) are
shown in frontal (a), back (b), and side (c)
views. The W1, W2, W3, and W4 are used
to measure the ranges, width, and distal-
fall-off of energies 106, 145, 172, and
221 MeV, respectively. (d) The RW3 block
is shown with the cutout for the PPC05
parallel plate chamber as well as the 3 cm
thickness buildup that is placed in front of
the chamber.
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2.E | Workflow
Our current daily QA workflow includes two daily QA plans based
on two sets of devices: (a) Sphinx, Lynx, and PPC05 and (b) MIMI
and HexaCheck.
2.E.1 | Sphinx, Lynx, and PPC05
A daily QA plan was generated in RayStation (v.6.1.1.2) with spot
map of four different energies (Fig. 4). In order to mimic patient
treatment, a daily QA plan is delivered using adaPT‐Deliver on Pro-
teusPLUS proton therapy system through ARIA. Dosimetry measure-
ments are performed using a single couch top setup with the Sphinx,
Lynx, and PPC05 chamber (Fig. 5) For PBS daily QA dosimetric
quantification, tests (Table 1) are categorized into: (a) spot position,
size, and skewness, (b) distal and proximal range, width, and DFO, (c)
radiation and imaging coincidence, (d) field homogeneity, and (e)
dose output. For evaluation and analysis, myQA software (IBA
Dosimetry, Schwarzenbruck, Germany) was utilized for tests #a–d
and an in‐house excel sheet and DOSE2 electrometer (IBA Dosime-
try, Schwarzenbruck, Germany) were used for test #e. Additionally,
verification of patient positioning system (PPS) displacement and
lasers alignment is accomplished with the same setup. The workflow
using Sphinx, Lynx, and PPC05 is presented in Fig. 6. The total time
for this workflow is from 15 to 20 min without system interruptions.
2.E.2 | MIMI and HexaCheck
A treatment plan with kV‐kV and CBCT setup fields was generated in
RayStation using the CT images of the MIMI phantom. The plan treat-
ment isocenter was defined at the center of the MIMI. The MIMI is
placed in the HexaCheck and indexed to the couch top such that MIMI
is aligned to the known translational and rotational offset shifts (Fig. 7)
Specifically, the known translational shifts were −13.4 mm in the lat-
eral, −9.1 mm in the longitudinal, and 10.8 mm in the vertical direc-
tions, whereas the known rotational shifts were 2.2° for the pitch,
−2.2° for the roll, and 3.5° for the yaw. First, a CBCT is acquired with
F I G . 4 . The spot map of a plan created
in RayStation for four different proton
beam energies (221, 172, 145, and
106 MeV) for the dosimetric testing of the
pencil beam scanning daily quality
assurance using the Sphinx and Lynx
devices is shown.
F I G . 5 . The daily couch top setup of the Sphinx, Lynx, and PPC05
for pencil beam scanning dosimetric testing of the daily quality
assurance procedure is shown. The gantry is set at 90° with the
robotic couch being set to 0°.
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gantry rotation from 270° to 90°, and the acquired CBCT images are
registered to the reference CT images of the MIMI in adaPT‐Insight to
obtain the 6D correction vector. The difference between the daily cor-
rection vectors (translational and rotational) and baseline values are
calculated using Eq. (1) provided below. After applying correction vec-
tor to the PPS, kV‐kV x‐ray imaging is performed to verify the final
position of the MIMI phantom is accurate. Both the kV‐kV x‐ray and
CBCT images are transferred to ARIA for offline review. The workflow
using MIMI and HexaCheck is presented in Fig. 8. The total time for
this workflow is about 10 min.
ΔðpÞ ¼ M(p) - B(p) (1)
where, p = translational (e.g., lateral) or rotational parameter (e.g.,
yaw); M(p) = daily measured value of parameter, p; B(p) = baseline
value of parameter, p; Δ(p) = difference between measured and
baseline values of parameter, p.
3 | RESULTS
The daily QA results presented herein are based on a set of 202 daily
measurements over the period of 10 months on an IBA gantry‐based
ProteusPLUS PBS proton therapy system. The analysis of results was
carried out in two steps. First, the relative difference (Δ) was calcu-
lated by comparing daily (D) measurements against baseline (B) mea-
surements. Second, a statistical process control (SPC) analysis was
performed to assess the temporal stability of each parameter and
determine whether the various parameters of the system were in sta-
tistical control. The QI Macros (KnowWare International, Denver, CO)
add‐on statistical analysis package (v.2018) for Microsoft Excel was
used for the statistical analysis. Specifically, for the Δ of each evalu-
ated parameter, the upper control limit (UCL), lower control limit (LCL),
and average values were calculated using a XbarR control chart in QI
Macros. An example of the control chart for the dose output of the
172 MeV beam as well as the distal range (R80) of the 221 MeV beam
is displayed in Fig. 9. The UCL and LCL are defined by +3σ and −3σ,
respectively, from the average value. The 3σ means 99.73% of the val-
ues lie within three standard deviations of the mean.
3.A | Dose output and field homogeneity
Dose output and field homogeneity were evaluated for energies of
172 and 221 MeV, respectively. Table 2 and Fig. 10 show that the
average Δ in dose output was −0.2% (range, −1.1%–1.5%) relative
to baseline, and the Δ in field homogeneity was within ±1% (range,
−1.0%–0.7%). The 3σ of the dose output and field homogeneity
were ±0.7% and ±0.3%, respectively (Table 2).
3.B | Energy, width, and DFO
The energy, width, and DFO were evaluated for 106, 145, 172, and
221 MeV energies. Table 2 shows the Δ in distal and proximal
ranges (R80) were within ±0.5 mm for all four energies. For both the
distal and proximal ranges, the 3σ (Table 2) of all four energies was
±0.3 mm. For both the width and DFO, the Δ was within ±0.4 mm.
The 3σ (Table 2) of width for all four energies was ±0.2 mm,
whereas the 3σ of DFO was ±0.1 mm for energies 145, 172, and
221 MeV and 0 mm for 106 MeV.
3.C | Spots characteristics
Spots characteristics (position, size, and skewness) were evaluated
for four spots (106, 145, 172, and 221 MeV). Table 3 and Figs. 11
TAB L E 1 Overview of daily quality assurance tests for a proton
pencil beam scanning delivery system.
Test items
Safety Door interlock (beam off)
Audio/visual monitor(s)
Intercom
Beam on indicator
Alarm indicator
X‐ray on indicator
Room radiation monitor
Room search/clear button
Beam pause
Beam stop
Beam delivery controller reset
Collisional interlocks
Mechanical,
imaging, and
OIS connectivity
Laser localization
Imaging and treatment coordinate
coincidence
Positioning/repositioning
(translational & rotational)
Gantry angle
Range shifter detection
Dual source kV‐kV x‐ray image acquisition
CBCT acquisition
Connectivity between OIS and
delivery unit software
X‐ray vs surface imaging isocenter
coincidence
Dosimetry Spot position
Spot sigma
Spot skewness
Distal range
Proximal range
Width
Distal-fall-off (DFO)
Imaging vs proton beam isocenter
coincidence
Field homogeneity
Dose output
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and 12 show that the Δ in spots positions (X & Y) was within
±1 mm, and the Δ in in‐air spot sigma (X & Y) was within ±10% for
all four spots. The 3σ (Table 3) evaluation of spot position showed
that all four spots had slightly lower value in y direction (±0.4 mm)
compared to the one in x direction (±0.6). For the in‐air spot sigma,
the 3σ was found to increase with beam energy, and it increased
from ±0.9% to ±2.1% for in‐air spot sigma X and from ±1.1% to
±3.6% for in‐air spot sigma Y. The Δ in spots skewness (X & Y) was
within ±0.5 for all four spots (Table 3). The 3σ of spot skewness ran-
ged from ±0.2 to ±0.3 (Table 3).
3.D | X‐ray vs proton beam coincidence
Table 2 and Fig. 13 show that the Δ in x‐ray and proton beam coin-
cidence (X and Y directions) was within ±1 mm except in one case
(Δ = 1.3 mm). The 3σ of beam coincidence was ±0.7 mm in X and
±0.5 mm in Y directions (Table 2).
3.E | Translational and rotational shifts
Figure 14 shows the Δ in translational and rotational shifts from
the baseline values. The Δ ranged from −1.0 to 2.3 mm in lat-
eral, from −1.8 to 0.9 mm in longitudinal, and from −1.8 to
1.3 mm in vertical directions. For rotational shifts, the Δ ranged
from −0.8° to 0.9° for pitch, from −0.6° to 1.4° for roll, and
from −0.7° to 0.8° for yaw. The 3σ of the translational shifts
was slightly higher in lateral (±0.8 mm) than in longitudinal
(±0.6 mm) and vertical (±0.6 mm) directions, whereas for the
rotational shifts, the 3σ was ±0.2° for yaw and ±0.3° for pitch
and roll (Table 4).
F I G . 6 . The workflow for the dosimetric component of the daily quality assurance of a pencil beam scanning treatment unit using the
Sphinx, Lynx, and PPC05 is shown.
F I G . 7 . The couch top setup of the MIMI and HexaCheck
phantoms at the predefined position of the LEONI six‐dimensional
robotic couch. The MIMI phantom is positioned with both
translational and rotational offsets applied as shown above.
RANA ET AL. | 35
4 | DISCUSSION
The daily QA program discussed in this work was designed with
a few concepts in mind, namely: (a) establish a comprehensive
QA program incorporating proposed recommendations from forth-
coming TG‐224,9 (b) mimic the typical patient treatment work-
flow to validate data transfer, and (c) utilize novel commercial
devices to facilitate comprehensive and efficient testing. Due to
the unique software infrastructure at our center, daily proton
therapy treatments are delivered using multivendor hardware and
associated software. Because of potential risks of connectivity
issues, testing connectivity among the OIS and beam delivery/
imaging systems on a daily basis helps validate the workflow
functionality and can potentially detect issues prior to patient
treatments. In developing a daily QA program for a PBS proton
therapy system, there is currently limited guidance regarding the
specific tests, frequency of testing, and tolerances for each test.
Part of the challenge with standardized guidance stems from the
variability in delivery technologies (e.g., gantry, fixed‐beam, etc.),
techniques (e.g., double scatter, uniform scanning, etc.) as well as
different IGRT imaging techniques (e.g., kV‐kV, CBCT, CT‐on‐rails,
etc.). Currently, there is an AAPM TG‐224 working on a report
to address these issues and provide recommendations; however,
as of date, there is no official publication. There is, however, a
growing consensus as to a limited set of tests and their accepted
frequency from recent publications.4–9 Although, it is important
to mention that the determination of action level tolerances still
remains a challenge.
Conceptionally, in attempting to establish tolerances for specific
tests of a quality assurance program, a number of strategies may
be employed to determine the tolerance action value. One such
approach is to follow the recommended tolerances established by
published guidelines that were conceived by the consensus of a
group of experienced users — that is, for example, an AAPM task
group report. A second could be to evaluate the impact on the
patient dose distribution due to variations in that specific parame-
ter. For example, there have been publications characterizing the
impact of spot size on treatment plan quality.15 A third approach is
to use statistical process control to evaluate whether specific
parameters are behaving in a stable and controlled manner.16,17
With this information, it is possible to use statistical methods to
determine the system specific action level tolerances due to the
system performance. In using statistical process control, the
methodology is to first establish a process of testing a parameter,
test and observe, and characterize the behavior of the specific
parameter — for example, dose output, spot size, spot position,
etc. — over a time period. By characterizing the behavior, it is pos-
sible to determine when a parameter is out of control and is statis-
tically an outlier. This helps provide guidance as to when to act. In
this study, 10 months’ worth of data was collected to characterize
the behavior of our proton PBS delivery system. Our goal was to
measure the stability of multiple parameters and establish toler-
ances based on our specific system performance and not on gen-
eric guidelines. With the assumption that a parameter value is
approximately distributed normally, control limits based purely on
the behavior of the variability can be generated. Using control
F I G . 8 . The workflow for the imaging component of the daily quality assurance of a pencil beam scanning treatment unit using the MIMI
and HexaCheck is illustrated.
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charts, a delivery system‐specific action level (3σ) table can be
determined for daily QA.
With regards to dose output, the AAPM TG 14218 recommends
the tolerance of 3% for photon and electron, whereas Lambert et
al.5 and Actis et al.6 have used a tolerance of 2% and Younkin et al.8
used tolerance of 1% for PBS protons. In our current daily QA setup,
dose output is typically measured by taking at least two readings
with a PPC05 chamber. The statistical process control analysis
results from the past 10 months show that the 3σ of dose output is
±0.7%, which is a tighter tolerance compared to the published litera-
ture.4–6,8,9 For proton range and energy, authors have used different
tolerances of 0.5 mm,8 1 mm,4,5 and 2 mm.6,7,9 For our 10‐month
data, we noticed the variation in range (R80) within ±0.5 mm for all
four energies evaluated (106, 145, 172, and 221 MeV). The 3σ of
daily range tolerance of ±0.3 mm is reasonable on ProteusPLUS PBS
proton machine if the institution uses the Sphinx and myQA soft-
ware for daily range verification.
Looking at proton beam characteristics such as in‐air spot size,
Lambert et al.5 and Bizzochi et al.7 evaluated in‐air spot size of a sin-
gle energy with tolerances of ±10% and ±15%, respectively. How-
ever, if the institution evaluates multiple spots of different energies
on a daily basis, a single tighter tolerance value for all energies may
not be ideal. For spots characteristics, we deliver four spots of dif-
ferent energies (106, 145, 172, and 221 MeV) and myQA software
is used to analyze the in‐air spot size (sigma). For a spot of
221 MeV, our daily measured in‐air spot sigma deviated from the
baseline value by up to ±9.5%, whereas for the lower energy spots
(106 and 145 MeV), the deviation of daily in‐air spot sigma from
baseline value was <±5%. The 3σ of in‐air spot size also showed a
similar trend such that there is an increase in deviation with energy.
Additionally, there can be difference in X and Y directions of in‐air
spot size, especially at higher energies, on an IBA ProteusPLUS pro-
ton therapy system. For spot position tolerance, there is no common
agreement among investigators. For instance, spot position tolerance
F I G . 9 . The XbarR control charts for the dose output and distal range (R80) are shown. Statistical process control methods were used to
determine the stability of the beam parameters. Upper control limit (UCL) = +3σ and lower control limit (LCL) = −3σ were used to determine if
individual measurements required action.
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of ±1 mm from Bizzochi et al.7 is more stringent than ±1.5 mm sug-
gested by Lambert et al.5 and Younkin et al.8 and ±2 mm applied by
Actis et al.6 Although our daily spot positions (a total of four spots
with energies 106, 145, 172, and 221 MeV) varied from baselines
values by up to ±0.9 mm on certain days, the 3σ of spot positions
was lower (±0.6 mm in X and ±0.4 mm in Y). Since the Sphinx and
Lynx are indexed on the couch top, the accuracy of robotic couch
could also potentially affect the spot positions results. Hence, the
verification of daily QA setup with planar kV x rays is essential to
reduce the uncertainties introduced by the user setup and robotic
couch. For our current daily QA protocol and workflow (Fig. 6), a
tighter spot position tolerance of ±0.6 mm is feasible.
For x‐ray and proton beam coincidence, we currently use a single
spot of energy 106 MeV. Based on 10 months results, the deviation
in coincidence was found to be within ±1.5 mm, which was used as
the tolerance by Lambert et al.5 The 3σ of beam coincidence (x ray
and proton) was found to be ±0.7 mm in X and ±0.5 mm in Y direc-
tions. As shown in Fig. 6, we use the setup field to drive the 6D
TAB L E 2 Results of dose output, field homogeneity, range, width, distal-fall-off (DFO), and x‐ray vs proton beam coincidence based on daily
QA measurements (n = 202).
Energy (MeV) Avg. Range
SPC
3σ UCL LCL
Dose output (%) E172 −0.2 −1.1–1.5 ±0.7 0.5 −0.8
Field homogeneity (%) E221 0.0 −1.0–0.7 ±0.5 0.5 −0.6
R80‐distal range (mm) E106 −0.1 −0.3–0.1 ±0.3 0.2 −0.3
E145 −0.2 −0.3–0.1 ±0.3 0.1 −0.4
E172 0.2 0.0–0.5 ±0.3 0.5 −0.1
E221 −0.2 −0.5–0.3 ±0.3 0.2 −0.5
R80‐proximal range (mm) E106 −0.1 −0.3–0.1 ±0.3 0.2 −0.4
E145 −0.2 −0.4–0.1 ±0.3 0.1 −0.5
E172 0.1 −0.3–0.4 ±0.3 0.4 −0.3
E221 −0.2 −0.5–0.5 ±0.3 0.1 −0.6
Width (mm) E106 0.0 0.0–0.1 ±0.2 0.2 −0.1
E145 0.0 −0.1–0.2 ±0.2 0.2 −0.1
E172 0.2 0.0–0.4 ±0.2 0.4 −0.1
E221 0.0 −0.2–0.3 ±0.2 0.2 −0.2
Distal-fall-off (mm) E106 0.0 −0.1–0.1 0 0.0 0.0
E145 0.0 0.0–0.1 ±0.1 0.2 −0.1
E172 0.0 0.0 – 0.1 ±0.1 0.1 0.0
E221 0.0 −0.1–0.1 ±0.1 0.1 −0.1
Beam coincidence‐X (mm) E106 0.4 −0.8–1.3 ±0.7 1.1 −0.4
Beam coincidence‐Y (mm) E106 0.1 −0.7–0.9 ±0.5 0.6 −0.4
A relative difference (Δ) was calculated by comparing daily (D) measurements against baseline (B) measurements. Upper control limit (UCL) and lower
control limit (LCL) are based on statics process control (SPC) charts. UCL = +3σ and LCL = ‐3σ are from the average value.
F I G . 10 . (Left) Daily dose output for 172 MeV pencil beam scanning (PBS) proton beam;(Right) Daily field homogeneity for 221 MeV PBS
proton beam. [The relative difference (Δ) was calculated by comparing daily (D) measurements (n = 202) against baseline (B) measurement.]
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robotic couch to its predefined position such that the fiducial (2 mm
in diameter) that is a part of our indexed couch top setup is at the
imaging isocenter. Once the portal kV‐kV x‐ray image of the setup is
acquired, the center of cross‐hair (imaging isocenter) is projected at
the center of fiducial manually. It was found that the combination of
accuracy of robotic couch, phantom setup, and manual alignment of
cross hair at the center of fiducial could affect the localization of the
fiducial at the imaging isocenter. Hence, the robust indexing of
the phantom along with well‐defined manual alignment process of
the fiducial with imaging isocenter is critical in determining the coin-
cidence of x‐ray and proton beam.
In our current patient treatment workflow, we typically acquire
CBCT images followed by orthogonal kV‐kV x‐ray images. Although
the use of Sphinx and Lynx for daily imaging QA would be more
effective in reducing total daily QA time in the treatment room,
we noticed that the CBCT acquisition and automatic image regis-
tration in adaPT Insight for Sphinx and Lynx is not optimal. Hence,
the MIMI phantom in conjunction with the HexaCheck is used to
assess the 6D correction vector, which is calculated based on the
automatic rigid registration of the acquired CBCT images to the
reference CT images of the MIMI Phantom. Lambert et al.5 and
Younkin et al.8 have provided ±1 mm as the tolerance of couch
correction vector. Both of these publications5,8 utilized the kV‐kV
x‐ray imaging of the DQA‐3 device to calculate the correction vec-
tor for translational shifts only, whereas we have utilized the CBCT
of the MIMI/HexaCheck to assess the 6D correction vector, which
TAB L E 3 Results of spots characteristics (position, sigma, and skewness) based on daily quality assurance measurements (n = 202).
Avg. Range
SPC
3σ UCL LCL
Spot position‐X (mm)
Spot1 (E106) 0.0 −0.8–0.8 ±0.6 0.6 −0.6
Spot2 (E145) −0.1 −0.9–0.7 ±0.6 0.5 −0.7
Spot3 (E172) −0.1 −0.9–0.7 ±0.6 0.6 −0.7
Spot4 (E221) 0.3 −0.5–0.9 ±0.6 0.9 −0.3
Spot position‐Y (mm)
Spot1 (E106) 0.3 −0.3–0.9 ±0.4 0.7 −0.1
Spot2 (E145) 0.2 −0.3–0.7 ±0.4 0.6 −0.2
Spot3 (E172) 0.3 −0.3–0.8 ±0.4 0.7 −0.1
Spot4 (E221) 0.3 −0.4–0.9 ±0.4 0.7 0.0
Spot sigma‐X (%)
Spot1 (E106) −0.3 −1.8–0.0 ±0.9 0.6 −1.2
Spot2 (E145) 0.8 −4.8–2.4 ±1.7 2.5 −1.1
Spot3 (E172) 1.3 −2.7–2.7 ±1.9 3.2 −0.4
Spot4 (E221) −3.8 −6.5–0.0 ±2.1 −1.7 −5.9
Spot sigma‐Y (%)
Spot1 (E106) 0.0 −1.8–3.6 ±1.1 1.1 −1.1
Spot2 (E145) 0.6 −4.8–4.8 ±2.0 2.6 −1.4
Spot3 (E172) −1.9 −7.9–5.3 ±2.7 0.9 −4.5
Spot4 (E221) −0.7 −9.4–9.4 ±3.6 2.8 −4.3
Spot skewness‐X
Spot1 (E106) 0.1 −0.1–0.2 ±0.2 0.3 −0.2
Spot2 (E145) 0.1 −0.1–0.3 ±0.3 0.3 −0.2
Spot3 (E172) 0.0 −0.3–0.3 ±0.3 0.3 −0.3
Spot4 (E221) 0.0 −0.3–0.3 ±0.3 0.3 −0.3
Spot skewness‐Y
Spot1 (E106) 0.0 −0.2–0.2 ±0.2 0.2 −0.2
Spot2 (E145) 0.2 −0.1–0.5 ±0.2 0.4 −0.1
Spot3 (E172) −0.2 −0.4–0.0 ±0.3 0.1 −0.5
Spot4 (E221) 0.0 −0.2–0.3 ±0.3 0.3 −0.3
A relative difference (Δ) was calculated by comparing daily (D) measurements (n = 202) against baseline (B) measurements. Upper control limit (UCL) and
lower control limit (LCL) are based on statics process control (SPC) charts. UCL = +3σ and LCL = −3σ are from the average value.
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includes both the translational and rotational shifts. Based on 202
sets of measurements, the 3σ of translational shifts (lateral, longitu-
dinal, and vertical) ranged from ±0.6 to ±0.8 mm, and the 3σ of
rotational shifts (pitch, roll, and yaw) ranged from ±0.2° to ±0.3°.
The variation in daily 6D correction vector in our current daily QA
setup is found to be mainly due to the combination of (a) repro-
ducibility of MIMI/HexaCheck setup on the couch top, (b) accuracy
of 6D LEONI robotic couch, (c) user dependency on selection of
region of interest (ROI) for image registration in adaPT Insight, and
(d) image registration algorithm implemented within adaPT Insight
imaging system.
In addition to planar kV x rays and CBCT, QA on the C‐RAD Cat-
alystHD surface imaging is performed daily by utilizing a vendor sup-
plied daily QA phantom. Following the TG‐147 daily QA
recommendations, the functionality of the CatalystHD system and
coincidence of the surface imaging and laser isocenter is verified.
F I G . 11 . The difference (mm) in positions X and Y of spot1 (106 MeV), spot2 (145 MeV), spot3 (172 MeV), and spot4 (221 MeV). [The
relative difference (Δ) was calculated by comparing daily (D) measurements (n = 202) against baseline (B) measurement.]
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Specifically, the C‐RAD daily QA phantom is aligned to the room
isocenter using the room/gantry lasers. Once positioned, the daily
QA phantom is imaged, and the agreement between the laser
isocenter and surface imaging isocenter is quantified. Tolerances and
stability have been previously reported by Stanley et al.19 Our cur-
rent surface imaging daily QA tests include the laser accuracy, func-
tionality of the system, and calculation of translational shifts
(tolerance ±1 mm).
Lastly, for many proton centers, efficiency is an important ele-
ment being that beam access is limited. Recently, published literature
have reported proton daily QA time of 10 min,8 20 min,7 and
30 min.5,6 At our center, the daily QA time is under 30 min, which
also includes the workflows presented in Fig. 6 and 8. The variation
of daily QA time among different studies is mainly due to an incon-
sistency in the number and type of daily QA tests being performed
at different institutions. For example, the coincidence of x‐ray and
F I G . 12 . The difference (%) in Sigma X and Y of spot1 (106 MeV), spot2 (145 MeV), spot3 (172 MeV), and spot4 (221 MeV). [The relative
difference (Δ) was calculated by comparing daily (D) measurements (n = 202) against baseline (B) measurement.]
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proton beam is tested by Lambert et al.5 only, and in‐air spot size is
reported by Lambert et al.,5 Actis et al.,6 and Bizzochi et al.7 Further-
more, none of the studies4–8 reported the CBCT acquisition and its
functionality as a part of daily QA. This could be due to
unavailability of CBCT in the treatment room or difference in daily
QA policies at the authors’ institutions.4–8 The inclusion of CBCT in
our daily QA workflow (Fig. 8) has certainly contributed about 5 min
toward the total daily QA time at our center. In addition of
F I G . 13 . X‐ray vs proton beam coincidence in x and y directions. A single spot of 106 MeV was used for the coincidence.
F I G . 14 . Difference between translational/rotational correction vectors and known offset (baseline) values for subsequent kV‐cone‐beam
computed tomography imaging daily quality assurance measurements (n = 202).
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calculating the 6D correction vectors by using CBCT, this test allows
us to test the functionality of x‐ray tube, collision detection soft-
ware, and adaPT Insight as well as transfer of CBCT images to the
OIS for offline review.
5 | CONCLUSION
With the increasing complexity of delivery, patient positioning, and
imaging systems, a robust and comprehensive daily QA program is
required to gain confidence in the performance of a proton therapy
system. The use of novel phantoms and dosimetry devices such as the
Sphinx in conjunction with the Lynx and HexaCheck/MIMI was shown
to provide a robust, consistent and efficient method of evaluating vari-
ous aspects of our delivery system which include PBS beam parame-
ters and imaging/couch accuracy. Our daily QA results from over
10 months demonstrate consistent beam stability of the ProteusPLUS
PBS proton therapy system. If CBCT is available, it is recommended to
test its functionality on a daily basis mimicking a patient treatment
scenario. The use of MIMI/HexaCheck can serve an accurate and
efficient tool to perform daily, 6D IGRT QA of the IBA adaPT Insight
software and LEONI robotic couch.
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